Analysts have set 12-month price targets for Glaukos, revealing an average target of $170.86, a high estimate of $200.00, and ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today ...

As an innovative platform that addresses critical challenges in glaucoma treatment, notably patient adherence and medication side effects, iDose positions Glaukos as a leader in procedural ...

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in ...

MINT, a stent-free platform, helps treat adult patients undergoing glaucoma angle surgery. The system utilizes a unique ...

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma ...

Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE ... company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...

Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases ...